Johanna Estes
Family · Mount Vernon, ILNPI 1558685156
Payments from drug & device makers
Across 129 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$743
- AstraZeneca$408
- Lilly USA, LLC$285
- AbbVie$209
- GSK$94
- Dexcom, Inc.$67
- plus $426 from 12 others
What the payments were for
- Food & beverage$2,232100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 51 | $743 |
| AstraZeneca | 23 | $408 |
| Lilly USA, LLC | 14 | $285 |
| AbbVie | 12 | $209 |
| GSK | 6 | $94 |
| Dexcom, Inc. | 3 | $67 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $59 |
| Pfizer | 3 | $52 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| Esperion Therapeutics, Inc. | 2 | $44 |
| Vanda Pharmaceuticals Inc. | 1 | $39 |
| Aimmune Therapeutics, Inc. | 2 | $36 |
| Novartis | 1 | $35 |
| Exact Sciences | 2 | $34 |
| Mylan Specialty L.p. | 2 | $30 |
| Boehringer Ingelheim | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Viatris Specialty LLC | 1 | $16 |
How this compares
$2,232 in reported general payments places this provider in the 85th percentile of 4,941 family providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 93 | $110,715 |
| JardianceEmpagliflozin | 47 | $53,616 |
| FarxigaDapagliflozin Propanediol | 51 | $49,614 |
| EliquisApixaban | 38 | $44,610 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $30,854 |
| MounjaroTirzepatide | 24 | $27,279 |
| TrulicityDulaglutide | 20 | $22,764 |
| XareltoRivaroxaban | 30 | $17,644 |
| LinzessLinaclotide | 12 | $17,481 |
| JanuviaSitagliptin Phosphate | 11 | $16,604 |
| TradjentaLinagliptin | 25 | $13,088 |
| RybelsusSemaglutide | 13 | $12,393 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $10,120 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $9,985 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $7,162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $743 | $123,108106 claims |
| Boehringer IngelheimJardiance, Tradjenta | $17 | $66,70472 claims |
| Lilly USA, LLCMounjaro, Trulicity | $285 | $50,04344 claims |
| AstraZenecaFarxiga | $408 | $49,61451 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $94 | $48,00173 claims |
| PfizerEliquis | $52 | $44,61038 claims |
| AbbVieLinzess, Synthroid | $209 | $18,98529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,941 family providers in Illinois.
Other family in Mount Vernon
- Amanda McKeeMount Vernon$242K
- Ruth CarricoChicago$582K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Brooke KennardBloomington$208K
- Amy BrownellElk Grove Village$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.